Finnland - finnska - Fimea (Suomen lääkevirasto)

medac gesellschaft fÜr klinische spezialprÄparate mbh - mitomycin - injektio/infuusiokuiva-aine, liuosta varten - 1 mg/ml - mitomysiini

Evrópusambandið - finnska - EMA (European Medicines Agency)

stemline therapeutics b.v. - tagraxofusp - lymphoma - antineoplastiset aineet - elzonris is indicated as monotherapy for the first-line treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (bpdcn).

Evrópusambandið - finnska - EMA (European Medicines Agency)

bristol myers squibb pharma eeig - fedratinib dihydrochloride monohydrate - myeloproliferative disorders; primary myelofibrosis - antineoplastiset aineet - inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are janus associated kinase (jak) inhibitor naïve or have been treated with ruxolitinib.

Finnland - finnska - Fimea (Suomen lääkevirasto)

as kalceks - dexamethasone sodium phosphate - injektio-/infuusioneste, liuos - 4 mg/ml - deksametasoni

Finnland - finnska - Fimea (Suomen lääkevirasto)

abboxia ab - dexamethasone sodium phosphate - injektio-/infuusioneste, liuos - 4 mg/ml - deksametasoni

Evrópusambandið - finnska - EMA (European Medicines Agency)

yes pharmaceutical development services gmbh - doksorubisiinihydrokloridia - breast neoplasms; ovarian neoplasms; multiple myeloma; sarcoma, kaposi - antineoplastiset aineet - celdoxome pegylated liposomal is indicated in adults:as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk. or treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant. for treatment of aids-related kaposi’s sarcoma (ks) in patients with low cd4 counts (< 200 cd4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).

Evrópusambandið - finnska - EMA (European Medicines Agency)

sanofi b.v. - klofarabiinia - prekursorisolujen lymfoblastinen leukemia-lymfooma - antineoplastiset aineet - akuutti lymfaattinen leukemia (kaikki) pediatrian potilailla, joilla on uusiutunut tai on tehonnut saatuaan vähintään kaksi ennen hoito hoitoon ja jos ei ole muita hoitovaihtoehto odotettavissa johtaa kestävä vastaus. turvallisuutta ja tehokkuutta on arvioitu ≤ 21-vuotiaiden potilaiden tutkimuksissa alustavan diagnoosin yhteydessä.

Finnland - finnska - Fimea (Suomen lääkevirasto)

baxter oy - mesna - injektioneste, liuos - 100 mg/ml - mesna

Finnland - finnska - Fimea (Suomen lääkevirasto)

leo pharma a/s - heparin sodium - injektioneste, liuos - 5000 iu/ml - hepariini

Finnland - finnska - Fimea (Suomen lääkevirasto)

leo pharma a/s - heparinum natricum - injektioneste, liuos - 25000 iu/ml - hepariini